Dr. Haskali graduated with a PhD in radiopharmaceutical sciences from the University of Melbourne. He then joined the Investigational Medicinal Products (IMP) team at Cyclotek Pty. Ltd. (Jan 2013 – Sep 2014), a Good Manufacturing Practice (GMP) laboratory for the production of TGA licensed radiopharmaceuticals. Dr. Haskali then furthered his academic and clinical expertise in the development of radiopharmaceuticals for PET imaging at the National Institute of Mental Health (NIMH) in the USA (Oct 2014 – Sep 2016) in Dr. Victor Pike’s lab, a pioneering and world leading radiopharmaceutical scientist. From Oct 2016, Dr. Haskali joined Peter MacCallum Cancer Centre (PMCC) as a senior radiopharmaceuticals scientist. Dr. Haskali is a certified radiopharmaceutical scientist by the Australasian College of Physical Scientists and Engineers in Medicine (ACPSEM) in their A1 limited category, and have formally established his laboratory as a nationally recognized centre for radiopharmaceutical sciences training. He currently sits on the professional standards board (PSB) of the ACSPEM as the national representative of radiopharmaceutical sciences in Australia. Dr Haskali's currently leads a clinical and research program in radiopharmaceutical sciences at the PMCC. His current research focus is involved with all aspects of Radiopharmaceutical Sciences including i) developing new methods for radiolabelling bioactive molecules, ii) design and synthesis of new radiotracers/theranostics for PET imaging and radionuclide therapy, iii) radiopharmacological evaluation of theranostics and small animal PET imaging, and iv) clinical provision of radiopharmaceuticals. Haskali has a strong personal interest in all chemical aspects of the discovery, development and evaluation of novel radioactive probes for molecular imaging with PET and targeted radionuclide therapy.